Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-β Small Molecule Inhibitor.
Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-β Small Molecule Inhibitor.
复制标题
DOI:
10.1016/j.neo.2016.08.008
复制
发表时间:
2016-12
期刊:
影响因子:
4.8
通讯作者:
Placantonakis, Dimitris
中科院分区:
文献类型:
--
作者:
Bayin, N. Sumru;Ma, Lin;Thomas, Cheddhi;Baitalmal, Rabaa;Sure, Akhila;Fansiwala, Kush;Bustoros, Mark;Golfinos, John G.;Pacione, Donato;Snuderl, Matija;Zagzag, David;Barcellos-Hoff, Mary Helen;Placantonakis, Dimitris
High-grade glioma (HGG), a deadly primary brain malignancy, manifests radioresistance mediated by cell-intrinsic and microenvironmental mechanisms. High levels of the cytokine transforming growth factor-β (TGF-β) in HGG promote radioresistance by enforcing an effective DNA damage response and supporting glioma stem cell self-renewal. Our analysis of HGG TCGA data and immunohistochemical staining of phosphorylated Smad2, which is the main transducer of canonical TGF-β signaling, indicated variable levels of TGF-β pathway activation across HGG tumors. These data suggest that evaluating the putative benefit of inhibiting TGF-β during radiotherapy requires personalized screening. Thus, we used explant cultures of seven HGG specimens as a rapid, patient-specific ex vivo platform to test the hypothesis that LY364947, a small molecule inhibitor of the TGF-β type I receptor, acts as a radiosensitizer in HGG. Immunofluorescence detection and image analysis of γ-H2AX foci, a marker of cellular recognition of radiation-induced DNA damage, and Sox2, a stem cell marker that increases post-radiation, indicated that LY364947 blocked these radiation responses in five of seven specimens. Collectively, our findings suggest that TGF-β signaling increases radioresistance in most, but not all, HGGs. We propose that short-term culture of HGG explants provides a flexible and rapid platform for screening context-dependent efficacy of radiosensitizing agents in patient-specific fashion. This time- and cost-effective approach could be used to personalize treatment plans in HGG patients.
登录
查看更多内容
影响因子:
11.2
作者:
Hardee ME;Marciscano AE;Medina-Ramirez CM;Zagzag D;Narayana A;Lonning SM;Barcellos-Hoff MH
通讯作者:
Barcellos-Hoff MH
DOI:
10.1056/nejmoa1407279
发表时间:
2015-06-25
期刊:
The New England journal of medicine
影响因子:
--
作者:
Eckel-Passow JE;Lachance DH;Molinaro AM;Walsh KM;Decker PA;Sicotte H;Pekmezci M;Rice T;Kosel ML;Smirnov IV;Sarkar G;Caron AA;Kollmeyer TM;Praska CE;Chada AR;Halder C;Hansen HM;McCoy LS;Bracci PM;Marshall R;Zheng S;Reis GF;Pico AR;O'Neill BP;Buckner JC;Giannini C;Huse JT;Perry A;Tihan T;Berger MS;Chang SM;Prados MD;Wiemels J;Wiencke JK;Wrensch MR;Jenkins RB
通讯作者:
Jenkins RB
影响因子:
15.9
作者:
Hussain, S. Farzana;Yang, David;Heimberger, Amy B.
通讯作者:
Heimberger, Amy B.
影响因子:
3.4
作者:
Costes, SV;Boissière, A;Barcellos-Hoff, MH
通讯作者:
Barcellos-Hoff, MH
影响因子:
1.7
作者:
Jaskova, Katarina;Pavlovicova, Michaela;Jurkovicova, Dana
通讯作者:
Jurkovicova, Dana